Symbiotec Pharmalab Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹270(27.33%)
Premium (ELP)
Subscription for Symbiotec Pharmalab Limited's Initial Public Offering is currently underway, targeting total proceeds of 1,77,86,442 Shares. The offering composition includes 15,21,261 Shares in new capital infusion and ₹1607.00 Cr in existing shareholder sales.
The active price band of ₹938 to ₹988 and minimum lot requirement of 15 shares define the current investment parameters. Market participants are actively evaluating this opportunity during the subscription window.
The application deadline is fast approaching on Aug 27, 2026. Following Subscription closure, allotment will be processed on Aug 28, 2026, leading to the anticipated listing on Sep 01, 2026 at the NSE, BSE exchange platform.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company that develops and manufactures active pharmaceutical ingredients, nutritional ingredients, and specialty products for both domestic and international markets. The company focuses on research-based manufacturing, strong quality standards, and sustainable processes, serving industries like pharmaceuticals, nutraceuticals, and wellness with high-quality and innovative products. With over 30 years of experience, it has grown from a small lab-scale steroid API manufacturer into a large, fully integrated company with approvals from global authorities like the US FDA, EU-GMP, and Korea’s Ministry of Food and Drug Safety. As of June 30, 2025, the company operates two large-scale manufacturing facilities with a chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium (GMP) is based on market buzz and unofficial trading. It should not be considered as the guaranteed listing price. Always refer to the RHP and seek advice from a financial expert before making investment decisions.
💡 Read our detailed guide: What is IPO Grey Market Premium (GMP) & How It Works?•📈 Track all live rates on IPO GMP Today
- Global Leadership in Steroidal APIs: Symbiotec Pharmalab has strong expertise and an established position in manufacturing corticosteroid and steroidal-hormone APIs, supporting its presence in the global pharmaceutical ingredients market.
- Long-Standing Customer Relationships: The company has built strong relationships with domestic and international customers, supporting recurring business opportunities and market stability.
- Vertically Integrated Manufacturing: The company operates a multi-scale, vertically integrated manufacturing platform, enabling better process control, operational efficiency, and reliable production.
- Regulatory & Quality Compliance Risk: The company's facilities undergo inspections and audits by regulators and customers. Any manufacturing or quality failure could lead to regulatory action, reputational damage, and financial losses.
- Dependence on Export Markets: A significant portion of revenue comes from international customers. Changes in global markets, trade conditions, or difficulties in managing overseas operations could affect revenue and profitability.
- Dependence on Imported Raw Materials: The company sources some raw materials from countries such as China and the United States. Import restrictions, geopolitical developments, or supply disruptions could affect raw material availability and increase costs.
- Anil Satwani
- Kashish Satwani
- Sushil Satwani
- Satwani Holdings LLP
Symbiotec Pharmalab Limited
Link Intime India Private Limited